接受奥希替尼治疗的EGFR突变非小细胞肺癌患者的心脏事件与生存
该队列研究在台湾一家三级学术转诊中心纳入2019年9月1日至2022年7月31日开始EGFR TKIs治疗的401例EGFR突变非小细胞肺癌患者,中位随访23.2个月(IQR 15.2-31.5),随访至2024年1月31日完成。奥希替尼组195例(48.6%)与其他EGFR TKIs组206例(51.4%)比较,CTRCEs发生率为29例(14.9%)vs 9例(4.4%)(HR 3.37,95%CI 1.56-7.26,P=.002);校正心血管危险因素后校正亚分布HR 4.00(95%CI 1.81-8.85,P<.001)。CTRCEs与总生存独立相关(HR 4.02,95%CI 2.44-6.63,P<.001)。作者认为这些发现凸显了在这类患者中持续进行心脏监测的必要性,无论是否存在既存心脏危险因素。
要点
- 奥希替尼组CTRCEs发生29例(14.9%),其他EGFR TKIs组9例(4.4%),HR 3.37(95%CI 1.56-7.26,P=.002)。
- 校正年龄、性别、吸烟、饮酒、体质指数、心血管合并症、胸部放疗及心血管药物后,奥希替尼组CTRCEs的校正亚分布HR 4.00(95%CI 1.81-8.85,P<.001)。
- CTRCEs与总生存独立相关:HR 4.02(95%CI 2.44-6.63,P<.001)。
- CTRCEs包括新发心律失常、瓣膜性心脏病(中度及以上)、心肌梗死和心力衰竭。
- 作者认为,无论是否存在既存心脏危险因素,这类患者均需持续进行心脏监测。
适用人群与场景
- 2019年9月1日至2022年7月31日在台湾国立成功大学医院(一家学院医院及三级学术转诊中心)开始EGFR TKIs治疗的EGFR突变非小细胞肺癌患者,共401例(女性253例[63.1%],平均[SD]年龄69.2[11.3]岁)。
- 奥希替尼组195例(48.6%),其他EGFR TKIs组206例(51.4%)。
- 中位随访23.2个月(IQR 15.2-31.5),随访至2024年1月31日完成。
研究设计与关键结果
- 研究类型:队列研究,单中心(台湾国立成功大学医院),回顾性分析401例EGFR突变非小细胞肺癌患者。
- 暴露:奥希替尼(195例)vs 其他EGFR TKIs(206例)。
- 主要终点:CTRCEs(新发心律失常、瓣膜性心脏病[中度及以上]、心肌梗死和心力衰竭)。
- 奥希替尼组CTRCEs 29例(14.9%)vs 其他EGFR TKIs组9例(4.4%),HR 3.37(95%CI 1.56-7.26,P=.002)。
- 校正年龄、性别、吸烟、饮酒、体质指数、心血管合并症、胸部放疗及心血管药物后,奥希替尼组校正亚分布HR 4.00(95%CI 1.81-8.85,P<.001)。
- CTRCEs与总生存独立相关:HR 4.02(95%CI 2.44-6.63,P<.001)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现凸显了在这类患者中持续进行心脏监测的必要性,无论是否存在既存心脏危险因素。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although it has been reported that osimertinib mesylate provides better survival benefits compared with first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), it remains unclear whether osimertinib is associated with more cancer therapy-related cardiac events (CTRCEs) compared with other EGFR TKIs, as does the extent of the association these adverse effects may have with overall survival. This issue is particularly critical due to the high prevalence of EGFR variants within Asian populations, including that of Taiwan.
OBJECTIVE: To compare CTRCEs and their association with survival in patients treated with osimertinib vs other EGFR TKIs.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study was conducted at the National Cheng Kung University Hospital, a college hospital and tertiary academic referral center in Taiwan. The median follow-up duration was 23.2 (IQR, 15.2-31.5) months. A total of 401 patients with EGFR-mutant non-small cell lung cancer (NSCLC) beginning treatment with EGFR TKIs from September 1, 2019, to July 31, 2022, were retrospectively analyzed. CTRCEs included newly emerging arrhythmias, valvular heart diseases (moderate and more), myocardial infarction, and heart failure and were analyzed after adjusting for age, sex, smoking, alcohol consumption, body mass index, cardiovascular comorbidities, thoracic radiotherapy, and cardiovascular medications. Follow-up was completed January 31, 2024.
EXPOSURE: Osimertinib.
MAIN OUTCOMES AND MEASURES: The Cox proportional hazards model was used to estimate CTRCEs in patients treated with osimertinib or other EGFR TKIs. Considering that death can lower the incidence of CTRCEs, the competing risk method was used to calculate CTRCEs after adjusting for potential confounders. Multivariable Cox proportional hazard regression analysis for overall survival was used to explore whether CTRCEs were independently associated with overall survival.
RESULTS: Among the 401 patients (253 [63.1%] female; mean [SD] age, 69.2 [11.3] years), 195 (48.6%) treated with osimertinib were matched with 206 (51.4%) treated with other EGFR TKIs. Occurrence of CTRCEs in patients receiving osimertinib was significantly higher compared with patients treated with other EGFR TKIs (29 [14.9%] vs 9 [4.4%]; hazard ratio [HR], 3.37; 95% CI, 1.56-7.26; P = .002). After adjustment for relevant cardiovascular risk factors, the HR of CTRCEs was significantly higher in the group treated with osimertinib (adjusted subdistribution HR, 4.00; 95% CI, 1.81-8.85; P < .001). In addition, CTRCEs were independently associated with overall survival (HR, 4.02; 95% CI, 2.44-6.63; P < .001).
CONCLUSIONS AND RELEVANCE: In this cohort study of patients with EGFR-mutant NSCLC, osimertinib was associated with a higher incidence of CTRCEs compared with other EGFR TKIs; CTRCEs were independently associated with overall survival. These findings highlight the need for ongoing cardiac monitoring in these patients, regardless of preexisting cardiac risk factors.
参考来源
- Lin CY, Chang WT, Su PL, et al. Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib. JAMA Netw Open. 2024. PMID: 39636639. doi:10.1001/jamanetworkopen.2024.48364
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。